TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15239254

Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 200 microg/day for 2 months followed by 20mg octreotide LAR every 4 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pravastatin (40-80 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Gemcitabine (80-90 mg/m2 over 24 hours weekly in cycles of 4 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control groups (not specified in the study)
Number of subjects: 58
Study: 12362007

Group type: EXPERIMENTAL
Intervention: Home-based intervention program including physical therapy
Number of subjects: 188

Group type: COMPARATOR
Intervention: Educational program (control)
Number of subjects: 188
Study: 9657579

Group type: EXPERIMENTAL
Intervention: ECSC prediction equations
Number of subjects: 12900

Group type: COMPARATOR
Intervention: Active smokers
Number of subjects: 12900
Study: 8020902

Group type: EXPERIMENTAL
Intervention: Ofloxacin (400 mg/day for 10 days, first intravenously then orally) plus intravenous bolus of amoxicillin plus clavulanic acid (1 g) before each endoscopy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Antibiotic therapy only in cases of established or suspected infection
Number of subjects: 91
Study: 2614487

Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 1069328

Group type: EXPERIMENTAL
Intervention: A group received KR (knowledge of results) to the full second during the first 20 trials and to .01th of a second during the second 20 trials.
Number of subjects: 24

Group type: COMPARATOR
Intervention: B group received KR to .01th of a second during the first 20 trials and to the full second during the second 20 trials.
Number of subjects: 24
Study: 29622506

Group type: EXPERIMENTAL
Intervention: Polypill (aspirin, statin, and two blood pressure lowering drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27197288

Group type: EXPERIMENTAL
Intervention: Progressively decreasing reduced nicotine content (RNC) cigarettes
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group smoking their own brand
Number of subjects: 158
Study: 24508648

Group type: EXPERIMENTAL
Intervention: N-back working memory paradigm (2-back)
Number of subjects: 51

Group type: COMPARATOR
Intervention: N-back working memory paradigm (0-back)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 51

Group type: COMPARATOR
Intervention: Passive visual stimulation
Number of subjects: 51
Study: 22465565

Group type: COMPARATOR
Intervention: Sucrose solution (sweet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menthol vapor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose octaacetate solution (bitter)
Number of subjects: 0
Study: 20607310

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stenting (5-Fr, 4-cm-long stent with a single pigtail at the duodenal end)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No pancreatic duct stenting (no-stent group)
Number of subjects: 70
Study: 17668874

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day, 20 mg/day, and 40 mg/day for 4 weeks
Number of subjects: 15
Study: 16261108

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous morphine (SC)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Continuous epidural morphine (ED)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DS)
Number of subjects: 73
Study: 12105163

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 679
Study: 10995135

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope in the activated position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 10
Study: 8826100

Group type: EXPERIMENTAL
Intervention: Ivermectin 150 micrograms/kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg with a fatty breakfast for three consecutive days
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 69
Study: 2291289

Group type: EXPERIMENTAL
Intervention: Poncho-like shirts made of cotton (A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Poncho-like shirts made of synthetic fibers (B, C, D)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy controls wearing poncho-like shirts
Number of subjects: 55
Study: 7197116

Group type: EXPERIMENTAL
Intervention: Animal protein-based diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Soy protein-based diet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both diets (animal and soy protein)
Number of subjects: 24
Study: 30293184

Group type: EXPERIMENTAL
Intervention: Filtek Silorane + Silorane System Adhesive
Number of subjects: 70

Group type: COMPARATOR
Intervention: Filtek Z250 + Clearfil SE Bond
Number of subjects: 70
Study: 28746019

Group type: EXPERIMENTAL
Intervention: Nurse consultation
Number of subjects: 213
Study: 25893651

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for 10 weeks prior to bariatric surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nutritional support and education (Control)
Number of subjects: 80
Study: 24032741

Group type: EXPERIMENTAL
Intervention: Third-trimester routine ultrasound
Number of subjects: 6780
Study: 21724838

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.01, 0.02, 0.04, or 0.06 mg protein/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Daily GH treatment (0.035 mg protein/kg for seven doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (0.06 mg protein/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NNC126‐0083 (all doses)
Number of subjects: 30
Study: 19190658

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (A/V)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Amlodipine (A)
Number of subjects: 572
Study: 17683452

Group type: EXPERIMENTAL
Intervention: Home-based Early Intensive Behavioural Interventions (EIBI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Autism-specific nursery provision
Number of subjects: 44
Study: 14752594

Group type: EXPERIMENTAL
Intervention: Burch urethropexy (BU)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Burch urethropexy (BU) with concomitant abdominal paravaginal repair (APR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Burch urethropexy (BU) only
Number of subjects: 73
Study: 11846327

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conjugated equine estrogen plus medroxyprogesterone acetate (CCEP) 0.625 mg plus 5 mg daily
Number of subjects: 116
Study: 9728260

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (0.7 MAC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (0.7 to 1.3 MAC)
Number of subjects: 41
Study: 8042718

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study: 3109661

Group type: EXPERIMENTAL
Intervention: Sprinkler needle
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional needle
Number of subjects: 21
Study: 31609077

Group type: EXPERIMENTAL
Intervention: MAS062D lotion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hydrophilic cream
Number of subjects: 24
Study: 30053279

Group type: COMPARATOR
Intervention: 0 g protein (Group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 7 g protein (Group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 14 g protein (Group C)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 21 g protein (Group D)
Number of subjects: 28
Study: 28693622

Group type: EXPERIMENTAL
Intervention: Social Recovery Therapy (SRT) plus optimised treatment as usual (enhanced standard care)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Enhanced standard care alone
Number of subjects: 270
Study: 25713280

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental developmental index <70 at 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal IQ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IQ scores of 70 to 84
Number of subjects: 0
Study: 23007142

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 20
Study: 17272948

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual therapy
Number of subjects: 0
Study: 14585937

Group type: EXPERIMENTAL
Intervention: Fondaparinux (5.0, 7.5, or 10.0 mg subcutaneously once daily)
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Unfractionated heparin (continuous intravenous infusion)
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 2213

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2213
Study: 10875589

Group type: EXPERIMENTAL
Intervention: Simultaneous antegrade/retrograde reperfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Retrograde reperfusion only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 8953998

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard contact (SC)
Number of subjects: 50
Study: 1750102

Group type: EXPERIMENTAL
Intervention: 300 mg base chloroquine once weekly
Number of subjects: 49

Group type: COMPARATOR
Intervention: 200 mg daily proguanil
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 25 mg base chloroquine/kg (25 CQ) over three days for treatment of breakthroughs
Number of subjects: 49
Study: 7102531

Group type: EXPERIMENTAL
Intervention: Oral pindolol 5 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral pindolol 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral pindolol 15 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral pindolol 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol 30 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous pindolol 0.045 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol 0.3 mg/kg
Number of subjects: 16
Study: 28727703

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 7 µ/kg
Number of subjects: 44
Study: 24750689

Group type: EXPERIMENTAL
Intervention: Dietary behavioural modification treatment with exercise
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dietary behavioural modification treatment without exercise
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study: 23807255

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment combined with orthognathic surgery
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Skeletal malocclusion questionnaire
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treatment outcomes satisfaction
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High OHRQoL scores
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: OHIP‐G14 scores
Number of subjects: 28
Study: 21724794

Group type: EXPERIMENTAL
Intervention: Self-management intervention with individualized contacts (two to ten) with nurses
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control group (less educated patients with only primary education)
Number of subjects: 361
Study: 19370737

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 16719602

Group type: EXPERIMENTAL
Intervention: Local anesthetic plus hypnosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anesthetic
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anesthetic plus attention
Number of subjects: 45
Study: 15071189

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg three times per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study: 11903914

Group type: EXPERIMENTAL
Intervention: i.v. erythromycin 2 mg kg‐1 over 20 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: sublingual isosorbide 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 32
Study: 9269060

Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 14
Study: 8330156

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no desmopressin)
Number of subjects: 12
Study: 2449904

Group type: EXPERIMENTAL
Intervention: PAF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PGE2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 8
Study: 28969438

Group type: EXPERIMENTAL
Intervention: 7,000-lux bright white light
Number of subjects: 46

Group type: COMPARATOR
Intervention: 50-lux dim red placebo light
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 26302850

Group type: EXPERIMENTAL
Intervention: 400 IU/day of vitamin D3
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 800 IU/day of vitamin D3
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both interventions (400 IU and 800 IU)
Number of subjects: 32
Study: 24633018

Group type: EXPERIMENTAL
Intervention: Sentinel Node Biopsy (SNB) plus Wide Local Excision (WLE)
Number of subjects: 5840

Group type: COMPARATOR
Intervention: Wide Local Excision (WLE) only (Observation group)
Number of subjects: 5840
Study: 23966145

Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation (IES)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo stimulus (same protocol without electrical output)
Number of subjects: 11
Study: 20174950

Group type: EXPERIMENTAL
Intervention: SILS cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Classic laparoscopic cholecystectomy
Number of subjects: 40
Study: 18586645

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) group - 6 fish oil capsules per day (0.65 g DHA and 0.10 g EPA/day) for 3 months
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group - Soybean oil capsules
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: DHA group
Number of subjects: 233
Study: 16875902

Group type: EXPERIMENTAL
Intervention: Prevention pacing therapies (PPTs)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 546
Study: 14633951

Group type: EXPERIMENTAL
Intervention: PegIFN 0.5 microg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PegIFN 1.0 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11709865

Group type: EXPERIMENTAL
Intervention: Training (educational intervention)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 105
Study: 8784909

Group type: EXPERIMENTAL
Intervention: Infant formulas with iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant formulas with low iron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy formulas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein hydrolyzate formulas
Number of subjects: 0
Study: 1617318

Group type: EXPERIMENTAL
Intervention: TBI without lung shielding (n = 33)
Number of subjects: 64

Group type: COMPARATOR
Intervention: TBI with lung shielding (n = 31, control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TBI without lung shielding
Number of subjects: 64

Group type: COMPARATOR
Intervention: TBI with lung shielding (control group)
Number of subjects: 64
Study: 6240166

Group type: EXPERIMENTAL
Intervention: Oral tetracycline (1000 mg daily for 5 days, then 250 mg daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topical tetracycline (2% alcoholic solution)
Number of subjects: 49
Study: 30772130

Group type: EXPERIMENTAL
Intervention: Flexible Nasotracheal Intubation (FNI) using Ambu aScope Slim
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind Nasotracheal Intubation using Parker Endotrol tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Flexible Nasotracheal Intubation (FNI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blind Nasotracheal Intubation
Number of subjects: 20
Study: 30170579

Group type: EXPERIMENTAL
Intervention: BTI320 4 g (low dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BTI320 8 g (high dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29071948

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) therapy, treated by EA stimulation of bilateral Neiting (ST 44), Fenglong (ST 40), Zusanli (ST 36), Huaroumen (ST 24), Tianshu (ST 25), Wailing (ST 26), Shuidao (ST 28), Fujie (SP 14), Daheng (SP 13) for 25 min, once every other day, 3 times per week for 3 months.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment for weight reduction).
Number of subjects: 30
Study: 25170938

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) with ritonavir-boosted darunavir (DRV/r)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC) with ritonavir-boosted darunavir (DRV/r)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 85
Study: 21868752

Group type: EXPERIMENTAL
Intervention: 150 IU recombinant human follicle‐stimulating hormone (rFSH) administered on alternate days for 90 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Nonantioxidant vitamin supplements
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: rFSH treatment in patients with high basal DFI values (>15%)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Vitamin supplements in patients with high basal DFI values (>15%)
Number of subjects: 129
Study: 20620692

Group type: EXPERIMENTAL
Intervention: Sono-thrombolysis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of sono-thrombolysis and IVT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sono-thrombolysis alone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 32
Study: 17443649

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 10 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 30 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 70 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (all doses)
Number of subjects: 23
Study: 15267184

Group type: EXPERIMENTAL
Intervention: Somnoguard® mandibular advancement device (MAD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Somnoguard® MAD
Number of subjects: 20
Study: 12097457

Group type: EXPERIMENTAL
Intervention: Sestamibi
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: MDP
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: DMSA-V
Number of subjects: 158
Study: 10233320

Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum A toxin (200 mouse units)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sterile saline (placebo)
Number of subjects: 13
Study: 7846789

Group type: EXPERIMENTAL
Intervention: Intravenous and/or intracoronary thrombolysis (52 patients)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative treatment (placebo, 11 patients)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 63
Study: 2192212

Group type: EXPERIMENTAL
Intervention: Direct reconstruction of the esophagus
Number of subjects: 95

Group type: COMPARATOR
Intervention: Reconstruction 48-72 h after esophagectomy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Transmediastinal esophagectomy with direct reconstruction
Number of subjects: 95
Study: 28194

Group type: EXPERIMENTAL
Intervention: d‐amphetamine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nefopam (90 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29554338

Group type: EXPERIMENTAL
Intervention: Model OA consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27396241

Group type: EXPERIMENTAL
Intervention: linagliptin (5mg, monotherapy or combination therapy)
Number of subjects: 723

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 723
Study: 24342768

Group type: EXPERIMENTAL
Intervention: Intravenous application of 50 μg CCK-4
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CCK-4 application
Number of subjects: 30
Study: 23147984

Group type: EXPERIMENTAL
Intervention: 35 Hz NMES
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 Hz NMES
Number of subjects: 20
Study: 20085630

Group type: EXPERIMENTAL
Intervention: Ozone (0.3 ppm for 2 hours)
Number of subjects: 23
Study: 19033610

Group type: EXPERIMENTAL
Intervention: 3.6% carbohydrate plus 1% amino acids (AA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4.6% carbohydrate‐only (CHO)
Number of subjects: 12
Study: 16179769

Group type: EXPERIMENTAL
Intervention: Multi‐Cervical Unit (MCU)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Thera‐Band tubing (THER)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 32
Study: 11451319

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole daily for 3 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 29
Study: 9581210

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8001356

Group type: EXPERIMENTAL
Intervention: High-energy fast neutrons
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional megavoltage x-rays (photons)
Number of subjects: 10
Study: 2895630

Group type: EXPERIMENTAL
Intervention: Transscleral cryotherapy to the avascular retina
Number of subjects: 172

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 172